Novartis' TREM2 drug fails Phase 2 ALS trial

Novartis has scrapped development of a Phase 2 treatment candidate for amyotrophic lateral sclerosis, Endpoints News has learned. The Swiss pharma giant is ending work on VHB937/lifonebart in ALS, according to a